| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Review |
HankeWeatherall Institute of Molecular Medicine, MRC Human Immunology Unit, University of Oxford, The John Radcliffe, Oxford OX3 9DS, UK
Correspondence
Tomá Hanke
tomas.hanke{at}imm.ox.ac.uk
Candidate human immunodeficiency virus type 1 (HIV-1) vaccines focusing on T-cell induction, constructed as pTHr.HIVA DNA and modified vaccinia virus Ankara (MVA).HIVA, were delivered in a heterologous prime–boost regimen. The vaccines were tested in several hundred healthy or HIV-1-infected volunteers in Europe and Africa. Whilst larger trials of hundreds of volunteers suggested induction of HIV-1-specific T-cell responses in <15 % of healthy vaccinees, a series of small, rapid trials in 12–24 volunteers at a time with a more in-depth analysis of vaccine-elicited T-cell responses proved to be highly informative and provided more encouraging results. These trials demonstrated that the pTHr.HIVA vaccine alone primed consistently weak and mainly CD4+, but also CD8+ T-cell responses, and the MVA.HIVA vaccine delivered a consistent boost to both CD4+ and CD8+ T cells, which was particularly strong in HIV-1-infected patients. Thus, whilst the search is on for ways to enhance T-cell priming, MVA is a useful boosting vector for human subunit genetic vaccines.
Published online ahead of print on 5 October 2006 as DOI 10.1099/vir.0.82493-0.
This article has been cited by other articles:
|
|
 |
|
  B. C. G. de Alencar, P. M. Persechini, F. A. Haolla, G. de Oliveira, J. C. Silverio, J. Lannes-Vieira, A. V. Machado, R. T. Gazzinelli, O. Bruna-Romero, and M. M. Rodrigues Perforin and Gamma Interferon Expression Are Required for CD4+ and CD8+ T-Cell-Dependent Protective Immunity against a Human Parasite, Trypanosoma cruzi, Elicited by Heterologous Plasmid DNA Prime-Recombinant Adenovirus 5 Boost Vaccination Infect. Immun., October 1, 2009; 77(10): 4383 - 4395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Burgers, G. K. Chege, T. L. Muller, J. H. van Harmelen, G. Khoury, E. G. Shephard, C. M. Gray, C. Williamson, and A.-L. Williamson Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons J. Gen. Virol., February 1, 2009; 90(2): 468 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Wilson, M. J. Newman, B. D. Livingston, S. MaWhinney, J. E. Forster, J. Scott, R. T. Schooley, and C. A. Benson Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy Clin. Vaccine Immunol., June 1, 2008; 15(6): 986 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Geiben-Lynn, J. R. Greenland, K. Frimpong-Boateng, and N. L. Letvin Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses Clin. Vaccine Immunol., April 1, 2008; 15(4): 691 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-J. Im, N. Saubi, G. Virgili, C. Sander, D. Teoh, J. M. Gatell, H. McShane, J. Joseph, and T. Hanke Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding J. Virol., September 1, 2007; 81(17): 9408 - 9418. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
